参考文献/References:
[1] 孙凤艳.医学神经生物学.上海:上海科学技术出版社,2008:213.
[2] 李国彰.神经生理学.北京:人民卫生出版社,2007:75-77.
[3] Wang HC, Zuo CT, Guan YH. Research on receptors related to acupuncture analgesia and positron emission tomography radioligands:a review. Zhong Xi Yi Jie He Xue Bao, 2009, 7(6):575-581.
[4] Varnäs K, Hall H, Bonaventure P, et al. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using[(3)H] GR 125743. Brain Res, 2001, 915(1):47-57.
[5] Rosell DR, Thompson JL, Slifstein M, et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol Psychiatry, 2010, 67(12):1154-1162.
[6] Yatham LN, Liddle PF, Erez J, et al. Brain serotonin-2 receptors in acute mania. Br J Psychiatry, 2010, 196(1):47-51.
[7] Monti JM. The role of dorsal raphe nucleus serotonergic and nonserotonergic neurons, and of their receptors, in regulating waking and rapid eye movement (REM) sleep. Sleep Med Rev, 2010, 14(5):319-327.
[8] Kumar JS, Mann JJ. PET tracers for 5-HT (1A) receptors and uses thereof. Drug Discov Today, 2007, 12(17-18):748-756.
[9] Shiue CY, Shiue GG, Mozley PD, et al. P-[18F]-MPPF:a potential radioligand for PET studies of 5-HT1A receptors in humans. Synapse, 1997, 25(2):147-154.
[10] Passchier J, van Waarde A, Pieterman RM, et al. Quantitative imaging of 5-HT (1A) receptor binding in healthy volunteers with[(18) f] p-MPPF. Nucl Med Biol, 2000, 27(5):473-476.
[11] Defraiteur C, Lemaire C, Luxen A, et al. Radiochemical synthesis and tissue distribution of p-[18F] DMPPF, a new 5-HT1A ligand for PET, in rats. Nucl Med Biol, 2006, 33(5):667-675.
[12] 张现忠,庞燕,范卫卫,等.一种潜在5-HT1A脑受体显像剂99Tcm-Bicine/HYNIC-MPP2的制备及其生物性能.核化学与放射化学,2009,31(4):206-211.
[13] Passchier J, van Waarde A. Visualisation of serotonin-1A(5-HT1A) receptors in the central nervous system. Eur J Nuel Med, 2001, 28(1):113-129.
[14] Lemoine L, Verdurand M, Vacher B, et al.[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur J Nucl Med Mol Imaging, 2010, 37(3):594-605.
[15] Pierson ME, Andersson J, Nyberg S, et al.[11C]AZ 10419369:a selective 5-HT1B receptor radioligand suitable for positron emission tomography(PET). Characterization in the primate brain. Neuroimage, 2008, 41(3):1075-1085.
[16] Nabulsi N, Huang Y, Weinzimmer D, et al. High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using[11C]P943. Nucl Med Biol, 2010, 37(2):205-214.
[17] Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev, 2008, 108(5):1501-1516.
[18] Debus F, Herth MM, Piel M, et al. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. Nucl Med Biol, 2010, 37(4):487-495.
[19] Manaer L, Gillings N, Madsen K, et al. Brain imaging of serotonin 4 receptors in humans with[11C] SB207145-PET. Neuroimage, 2010, 50(3):855-861.
[20] Xu R, Hong J, Pike VW. Synthesis of high-affinity SB207710 analogs as potential brain 5-HT4 receptor radioligands for PET imaging. J label Comp Radiopharm, 2009, 52:S425.
[21] Berney A, Nishikawa M, Benkelfat C, et al. An index of 5-HT synthesis changes during early antidepressant treatment alpha-[11C] methyl-L-tryptophan PET study. Neurochem Int, 2008, 52(4-5):701-708.
[22] HuangY, Hwang DR, Bae SA, et al. A new positron emission tomography imaging agent for the serotonin transporter synthesis, pharmacological characterization, and kinetic analysis of[11C] 2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylpenylamine ([11C]AFM). Nucl Med Biol, 2004, 31(5):543-556.
[23] Huang Y, Narendran R, Bae SA, et al. A PET imaging agent with fast kinetics:synthesis and in vivo evaluation of the serotonin transporter ligand[11C]2-[2-dimethylaminomethylphenylthio)]-5-fluo-rophenylamine ([11C]AFA).Nucl Med Biol, 2004, 31(5):727-738.
[24] Shiue GG, Choi SR, Fang P, et al. N,N-dimethyl-2-(2-amino-4-(18) F-fluorophenylthio)-benzylamine(4-(18)F-ADAM):an improved PET radioligand for serotonin transporters. J Nucl Med, 2003, 44(12):L890-1897.
[25] Praschak-Rieder N, Hussey D, Wilson AA, et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitortreated depression:an[(18)F]MPPF positron emission tomography study. Biol Psychiatry, 2004, 56(8):587-591.
[26] Yasuno F, Suhara T, lchimiya T, et al. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry, 2004, 55(5):439-444.
[27] Frankle WG, Lombardo I, Kegeles LS, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder:a positron emission tomography imaging study with[11C] WAY 100635. Psychopharmacology(Berl), 2006, 189(2):155-164.
[28] Rasmussen H, Erritzne D, Andersen R, et al. Decreased frontal ser otonin2A receptor binding in antipsychotic-naive patients with firstepisode schizophrenia. Arch Gen Psychiatry, 2010, 67(1):9-16.
[29] Galusca B, Costes N, Zito NG, et al. Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1 A receptor binding in right frontotemporal cortex of both lean and recovered patients:[18F] MPPF PET scan study. Biol Psychiatry, 2008,64(11):1009-1013.
[30] Merlet I, Ryvlin P, Costes N, et al. Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage, 2004, 22(2):886-896.
[31] Kepe V, Barrio JR, Huang SC, et al. Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci USA, 2006, 103(3):702-707.
[32] Derry C, Benjamin C, Bladin P, et al. Increased serotonin receptor availability in human sleep:evidence from an[18F]MPPF PET study in narcolepsy. Neuroimage, 2006, 30(2):341-348.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]蔡莉,高硕.PET在精神分裂症中的研究进展[J].国际放射医学核医学杂志,2011,35(2):69.[doi:10.3760/cma.j.issn.1673-4114.2011.02.002]
CAI Li,GAO Shuo.Progress of PET imaging in Schizophrenia[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):69.[doi:10.3760/cma.j.issn.1673-4114.2011.02.002]